“Paxillin A Diagnostic Biomarker: Immunohistochemical Comparison Between Ameloblastoma And Odontogenic Keratocyst”
DOI:
https://doi.org/10.64252/91wwj038Keywords:
Paxillin, Ameloblastoma, odontogenic tumours, odontogenic keratocyst and Odontogenic cyst.Abstract
INTRODUCTION- Paxillin, a cytoskeletal adaptor protein, is implicated in tumorigenesis and cellular proliferation, making it a promising therapeutic target for odontogenic tumors and cysts. Understanding its molecular signaling may aid in developing novel therapies to reduce recurrence and invasiveness. This study evaluates Paxillin expression in odontogenic keratocysts and ameloblastomas, aiming to support future research on targeted inhibitors and personalized treatment strategies.
AIM-: To evaluate and compare immune histochemical expression of paxillin in Ameloblastoma and Odontogenic keratocyst.
OBJECTIVE-: 1. To identify and quantify immuno-histochemical expression of paxillin in histopathological confirmed cases of Ameloblastoma (group 1) 2. To identify and quantify Immuno- Histochemical Expression of paxillin in histopathological confirmed cases of Odontogenic keratocyst. (Group 2) 3. To evaluate and co- relate the findings within and between the group.
MATERIALS AND METHODOLOGY- This cross-sectional study analyzed 56 formalin-fixed, paraffin-embedded tissue specimens—comprising 28 ameloblastoma and 28 odontogenic keratocyst cases. Immunohistochemical staining was performed using anti-paxillin (PXN) antibody.
RESULTS: Paxillin expression in ameloblastomas was mainly peripheral, especially in proliferative zones, whereas OKCs showed positivity in basal and suprabasal epithelial layers. Moderate staining was observed in 35.71% of cases, weak in 58.93%, and negative expression occurred in 5.36% (only in OKCs). Ameloblastomas showed a higher mean staining score (4.71 ± 1.41) than OKCs (3.64 ± 1.41), with statistical significance noted only for staining scores.
CONCLUSION: Elevated paxillin expression in ameloblastoma underscores its aggressive nature. Targeting paxillin family proteins and their downstream signaling pathways may offer valuable diagnostic and therapeutic opportunities.
